Reactive Astrocytes: Cellular and Molecular Cues to Biological Function
Overview
Authors
Affiliations
For several decades, the reactive gliosis that occurs after an injury to the CNS has been considered one of the major impediments to axonal regeneration. Nevertheless, recent studies have suggested that in certain conditions, reactive astrocytes may provide a permissive substratum to support axonal regrowth. The important criteria, allowing for the distinction between permissive and non-permissive gliosis, are the ultrastructural 3D organization of the scar and more importantly the recognition molecules expressed by reactive astrocytes. Reactive astrocytes express surface molecules and produce various neurotrophic factors and cytokines. The latter in turn might modulate the production of recognition molecules by reactive astrocytes, allowing them to support post-lesional axonal regrowth. Although numerous recent articles have focused on cytokines and cell adhesion molecules, scant attention has been paid to reactive astrocytes. Reactive astrocytes should be considered a key element, like neurons, of a dynamic environment, thus forming with neurons a functional unit involved in homeostasis, plasticity and neurotransmission. Attempts are in progress to identify molecular markers for reactive astrocytes.
Unveiling the hidden culprit: How the brain-gut axis fuels neuroinflammation in ischemic stroke.
Ma B, Chan T, Lo B Surg Neurol Int. 2024; 15:394.
PMID: 39640340 PMC: 11618647. DOI: 10.25259/SNI_703_2024.
Neuropathic Pain Induced by Spinal Cord Injury from the Glia Perspective and Its Treatment.
Ye Y, Su X, Tang J, Zhu C Cell Mol Neurobiol. 2024; 44(1):81.
PMID: 39607514 PMC: 11604677. DOI: 10.1007/s10571-024-01517-x.
Immune responses drive chorioretinitis and retinal pathology after neonatal CMV infection.
McCord J, Han J, Staudt R, Philp N, Snyder C Sci Adv. 2024; 10(47):eadn6379.
PMID: 39565860 PMC: 11578184. DOI: 10.1126/sciadv.adn6379.
The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases.
Gogishvili D, Honey M, Verberk I, Vermunt L, Hol E, Teunissen C J Neurochem. 2024; 169(1):e16226.
PMID: 39289040 PMC: 11658191. DOI: 10.1111/jnc.16226.
Costa A, Micheli L, Sordi V, Ciampi C, Lucci J, Passani M Front Pharmacol. 2024; 15:1439811.
PMID: 39253374 PMC: 11381240. DOI: 10.3389/fphar.2024.1439811.